eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Merck Sharp & Dohme Limited

Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU
Telephone: +44 (0)1992 467 272
Fax: +44 (0)1992 479 292
Medical Information e-mail: medicalinformationuk@merck.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 27/01/2011
SPC Dexamethasone 4.0mg/ml injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27/01/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Jan-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



The SmPC has been amended to include the following text:

4.4       Special warnings and precautions for use

The results of a randomised, placebo-controlled study suggest an increase in mortality if methylprednisolone therapy starts more than two weeks after the onset of Acute Respiratory Distress Syndrome (ARDS). Therefore, treatment of ARDS with corticosteroids should be initiated within the first two weeks of onset of ARDS.

4.5       Interaction with other medicinal products and other forms of interaction

 

The effects of anticholinesterases are antagonised by corticosteroids in myasthenia gravis.

 

SmPC section headings were also revised in line wit the current EU QRD template.

Updated on 15/08/2008 and displayed until 27/01/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01-Mar-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Summary of Changes

 

4.4       Special warnings and special precautions for use

 

The following additional two paragraphs in bold text have been inserted:

 

Patients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with systemic steroids (see section 4.8).  Symptoms typically emerge within a few days or weeks of starting the treatment.  Risks may be higher with high doses/systemic exposure (see also section 4.5 for pharmacokinetic interactions that can increase the risk of side effects), although dose levels do not allow prediction of the onset, type severity or duration of reactions.  Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary.  Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected.  Patients/carers should also be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such reactions have been reported infrequently.

 

Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives.  These would include depressive or manic-depressive illness and previous steroid pyschosis.

 

4.8       Undesirable effects

 

Additional wording in bold text has been added.  Strikethrough text has been removed.

 

Neuropsychiatric

 

A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and aggravation of schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia have been reported.  Reactions are common and may occur in both adults and children.  In adults, the frequency of severe reactions has been estimated to be 5-6%.  Psychological effects have been reported on withdrawal of corticosteroids; the frequency is unknown

 

Psychological dependence, depression, insomnia and aggravation of schizophrenia. Increased intra-cranial pressure with papilloedema in children (pseudotumour cerebri), usually after treatment withdrawal.  Aggravation of epilepsy. Psychic disturbances ranging from euphoria to frank psychotic manifestations. Psychological dependence.

Updated on 21/09/2005 and displayed until 15/08/2008
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 13/09/2005 and displayed until 21/09/2005
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
Updated on 16/08/2005 and displayed until 13/09/2005
Reasons for adding or updating:
  • Change to section 1 - trade name
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change from BAN to rINN
  • Change to section 10 (date of (partial) revision of the text
Updated on 17/08/2004 and displayed until 16/08/2005
Reasons for adding or updating:
  • Change to section 1 - trade name
Updated on 25/03/2003 and displayed until 17/08/2004
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
Updated on 12/04/2002 and displayed until 25/03/2003
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
Updated on 25/02/2002 and displayed until 12/04/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   dexamethasone sodium phosphate